BioNTech says lung cancer drug candidate prolonged lives in trial
9 Articles
9 Articles
BioNTech Lung Cancer Drug Extends Survival Versus Chemotherapy
The German pharmaceutical company now reports positive data on an active substance against lunken cancer. The mean overall survival was 18.5 months.
For patients suffering from advanced lung cancer, there is often only chemotherapy or palliative care. A new drug from Biontech could give them some hope.
BioNTech announced on Monday that its drug candidate, gotistobart, showed a clinically meaningful survival benefit in a late-stage clinical trial for a type of lung cancer compared to standard treatment. We will also be covering similar topics at our Portfolio Investment Day conference on October 21. One of the biggest investment events of the year is coming up, where professional experts will tell you what to invest in now. Register here.
BioNTech says lung cancer drug candidate prolonged lives in trial
FRANKFURT, Sept 14 (Reuters) – BioNTech said on Monday that a late-stage trial showed its drug candidate gotistobart led to a clinically meaningful overall survival benefit in a certain form of lung cancer compared with standard treatment. It added that results from the PRESERVE-003 Phase 3 clinical trial involved patients with squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemoth…
BioNTech adds clinical weight to its oncology pivot at WCLC 2026 - European Biotechnology Magazine
New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously treated squamous NSCLC, while the company’s leading bispecific antibody pumitamig continues to generate encouraging signals across tumor types and in combination with an antibody-drug conjugate. The key question now is whether these early signals …
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
